My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Guardant Health, Inc. - Common Stock (NQ:GH)

178.70 +0.97 (+0.55%)

Streaming Delayed Price Updated: 3:22 PM EDT, Sep 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore

September 29, 2026

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

September 21, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

Topics Credit Cards

Testing & Diagnostics Services Stocks Q2 Results: Benchmarking Guardant Health (NASDAQ:GH)

September 15, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Guardant Health (NASDAQ:GH) a...

Via StockStory

1 Growth Stock to Add to Your Roster and 2 We Turn Down

September 08, 2026

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...

Via StockStory

Guardant Health (NASDAQ:GH) Shares Surge After Q2 Revenue Beat and Raised 2026 Outlook ↗

July 30, 2026

Via Chartmill

Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick ↗

June 15, 2026

Via Chartmill

Why Rule Breakers Buy a Stock That's Already "Won" ↗

August 31, 2026

You found a great company, then watched it double before you got round to buying.

Via The Motley Fool

Topics Death

Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate ↗

August 14, 2026

Guardant Health (NASDAQ:GH) highlighted growth across its oncology testing, minimal residual disease, and colorectal cancer screening businesses at the Canaccord Genuity Growth Conference, with co-CEOs...

Via MarketBeat

Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million ↗

August 12, 2026

Ian Clark exercised stock options at $50.57 and immediately liquidated the position as the precision oncology company trades near $160 per share.

Via The Motley Fool

Topics Regulatory Compliance

Guardant Health (GH) Q2 2026 Earnings Call Transcript ↗

August 07, 2026

Shield screening volumes more than doubled, with UnitedHealth coverage now active.

Via The Motley Fool

Topics Earnings

2 Cash-Burning Stocks to Target This Week and 1 We Find Risky

August 03, 2026

While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...

Via StockStory

Topics Energy

GH Q2 Deep Dive: Shield Coverage and Oncology Uptake Drive Strong Revenue Growth

August 01, 2026

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 44.3% year on year to $33...

Via StockStory

Guardant Health Q2 Earnings Call Highlights ↗

July 31, 2026

Guardant Health (NASDAQ:GH) reported second-quarter 2026 revenue of $335 million, up 44% from a year earlier, as growth accelerated across its oncology, biopharma and data, and screening businesses....

Via MarketBeat

Topics Earnings

Guardant Health (NASDAQ:GH) Delivers Strong Q2 CY2026 Numbers, Stock Soars

July 30, 2026

Diagnostics company Guardant Health (NASDAQ:GH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 44.3% year on year to $3...

Via StockStory

Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

July 28, 2026

Diagnostics company Guardant Health (NASDAQ:GH) will be announcing earnings results this Thursday after market close. Here’s what to look for. Guardant Healt...

Via StockStory

3 Mid-Cap Stocks We’re Skeptical Of

July 01, 2026

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...

Via StockStory

Why Are Guardant Health (GH) Shares Soaring Today

June 26, 2026

What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 5.4% in the afternoon session after several investment firms issued positive ...

Via StockStory

Topics Artificial Intelligence

Why Are Guardant Health (GH) Shares Soaring Today

June 24, 2026

What Happened? Shares of diagnostics company Guardant Health (NASDAQ:GH) jumped 6.1% in the morning session after its stock hit a 52-week high following rece...

Via StockStory

3 Russell 2000 Stocks We Approach with Caution

June 22, 2026

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...

Via StockStory

Topics Energy

Why Grail Could Be the Sleeper Stock Everyone's About to Notice ↗

June 08, 2026

Grail is on a quest to win in a $50 billion market.

Via The Motley Fool

1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds

June 05, 2026

Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses...

Via StockStory

Topics Bankruptcy

June 04, 2026

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...

Via StockStory

3 Unprofitable Stocks Walking a Fine Line

June 01, 2026

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...

Via StockStory

Topics Electric Vehicles

3 Reasons GH is Risky and 1 Stock to Buy Instead

June 01, 2026

Over the past six months, Guardant Health has been a great trade, beating the S&P 500 by 11.7%. Its stock price has climbed to $129.08, representing a health...

Via StockStory

Topics Bankruptcy Stocks Supply Chain

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗

May 31, 2026

This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.

Via The Motley Fool

Topics Regulatory Compliance

Testing & Diagnostics Services Stocks Q1 Earnings: Guardant Health (NASDAQ:GH) Firing on All Cylinders

May 28, 2026

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the testing & diagnostics services industr...

Via StockStory

3 Growth Stocks We’re Skeptical Of

May 26, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗

May 24, 2026

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Via The Motley Fool

Topics Regulatory Compliance

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗

May 24, 2026

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

Via The Motley Fool

Topics Regulatory Compliance

3 of Wall Street’s Favorite Stocks Walking a Fine Line

May 21, 2026

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.